Cardiology Today

Welcome to Cardiology Today – Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals. Listen to This Episode Your browser does not support the audio element. Episode Summary This episode covers 1 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology. Featured Research Articles Article 1: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. Journal: The New England journal of medicine PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879434 Summary: This double blind placebo controlled trial investigated digitoxin in heart failure patients with reduced ejection fraction. The study found no significant difference in the primary outcome of death from cardiovascular causes or hospitalization for heart failure between the digitoxin and placebo groups, suggesting digitoxin offers no benefit in this patient population. Full Episode Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. This double blind placebo controlled trial investigated digitoxin in heart failure patients with reduced ejection fraction. The study found no significant difference in the primary outcome of death from cardiovascular causes or hospitalization for heart failure between the digitoxin and placebo groups, suggesting digitoxin offers no benefit in this patient population. Thank you for listening to Cardiology Today. Keywords Medical Topics: Cardiology, Cardiovascular Medicine, Heart Disease, Clinical Research, Medical Education, Evidence-Based Medicine Journals: New England Journal of Medicine (NEJM), Journal of American College of Cardiology (JACC), Circulation, European Heart Journal, Nature Reviews Cardiology About Cardiology Today Cardiology Today provides concise, professional summaries of cutting-edge cardiovascular research for healthcare professionals, medical students, and cardiology enthusiasts. Each episode features the latest findings from top-tier medical journals, delivered in an accessible format perfect for staying current with advances in cardiac care. Subscribe to stay updated with the latest cardiology research • Share with colleagues • Follow for more medical contentThe post Digitoxin Fails to Improve Outcomes in HFrEF 09/01/25 first appeared on Cardiology Today.

Welcome to Cardiology Today – Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals. Listen to This Episode Your browser does not support the audio element. Episode Summary This episode covers 8 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology. Featured Research Articles Article 1: AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884219 Summary: This study demonstrated the therapeutic potential of KCNH2-specific suppression-and-replacement (KCNH2-SupRep) gene therapy in a transgenic rabbit model of SQT1. The gene therapy approach effectively targeted and corrected the genetic defect, offering a potential treatment strategy for this life-threatening condition. Article 2: Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884211 Summary: This analysis of the REBOOT trial found no significant difference in the effect of beta-blockers post-MI with LVEF > 40 percent between men and women. These findings suggest that current guidelines for beta-blocker use after MI can be applied equally to both sexes, even with preserved ejection fraction. Article 3: Hypokalaemia and atrial fibrillation detected by implanted loop recorders. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884202 Summary: This post hoc analysis of the LOOP study found an association between lower plasma potassium levels and increased daily atrial fibrillation (AF) burden in individuals at risk for stroke. Continuous ECG monitoring via implanted loop recorders allowed for the detection of these subtle, yet clinically relevant, potassium-AF associations. Article 4: Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884168 Summary: This study demonstrated that circulating levels of imidazole propionate (ImP), a gut microbiota-derived metabolite, are associated with increased cardiometabolic risk in patients with coronary artery disease. ImP levels may serve as a prognostic biomarker for identifying high-risk CAD patients. Article 5: Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial). Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884070 Summary: The EMPATICC trial investigated the safety and efficacy of heart failure therapies in patients with advanced cancer receiving specialized palliative care. The study aims to determine if these treatments can improve self-care ability in patients with cardiac wasting, dyspnea, and congestion. Article 6: Improving outcomes of atrial fibrillation ablation by integrated personalized lifestyle interventions: a randomized controlled trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884040 Summary: The POP-AF trial showed that a nurse-led, integrated lifestyle program improved outcomes after atrial fibrillation ablation. Patients receiving personalized lifestyle interventions experienced better ablation success compared to those receiving standard pre-ablation counseling. Article 7: Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884033 Summary: This large, retrospective study provides real-world incidence estimates for immune checkpoint inhibitor (ICI)-induced myocardial and muscle toxicities in cancer patients. The findings help to better define risk factors and prognostic indicators to improve management of these severe adverse drug reactions. Article 8: Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884032 Summary: This detailed analysis of the VICTOR trial found that vericiguat did not significantly reduce cardiovascular mortality in patients with heart failure and reduced ejection fraction (HFrEF) without recent worsening. These findings suggest that vericiguat may not provide a mortality benefit in this specific patient population. Full Episode Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome. This study demonstrated the therapeutic potential of KCNH2-specific suppression-and-replacement (KCNH2-SupRep) gene thera

Welcome to Cardiology Today – Episode recorded on September 01, 2025. Your source for the latest cardiology research findings from top medical journals. Listen to This Episode Your browser does not support the audio element. Episode Summary This episode covers 8 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology. Featured Research Articles Article 1: Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886063 Summary: This study characterizes hyperreactive reticulated platelets in CAD patients, identifying their prothrombotic molecular phenotype. The findings suggest that targeting these platelets could offer novel therapeutic strategies to improve outcomes in CAD patients. Article 2: Semaglutide promotes bone marrow-derived progenitor cell flux toward an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886061 Summary: The SEMA-VR CardioLink-15 trial demonstrates that semaglutide, a GLP-1RA, increases circulating vascular regenerative stem and progenitor cells. This suggests a potential mechanism by which semaglutide reduces cardiovascular events through promoting vessel repair and reducing atherothrombotic risk. Article 3: CRISPR activation to repair ECG abnormalities caused by a FLNC truncating variant in mice. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886060 Summary: This study demonstrates the potential of CRISPR activation to upregulate FLNC gene expression in mice with truncating variants, leading to repair of ECG abnormalities. This offers a promising gene-specific therapeutic strategy for FLNCtv-induced cardiomyopathy, for which no current targeted therapies exist. Article 4: Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884758 Summary: The DANCAVAS II trial evaluated population-based screening for cardiovascular disease in men aged 60-64. Results showed screening detected subclinical CVD but did not demonstrate significant all-cause mortality reduction within the trial’s timeframe. Article 5: Aspirin dosing after acute coronary syndrome with suspected aspirin resistance: the ANDAMAN trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884757 Summary: The ANDAMAN trial investigated twice-daily aspirin dosing in ACS patients with diabetes or suspected aspirin resistance. The study found that twice-daily aspirin did not reduce major adverse cardiovascular events compared to standard dosing in this high-risk population. Article 6: Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884558 Summary: The VICTORION-Difference trial demonstrates that inclisiran, a PCSK9 siRNA, effectively reduces LDL-C levels in patients with hypercholesterolemia when used as part of a combination treatment strategy. These findings support the use of inclisiran to achieve LDL-C goals and reduce atherosclerotic cardiovascular disease risk. Article 7: Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884439 Summary: This secondary analysis of the DAN-RSV trial examined the effectiveness of the RSVpreF vaccine in individuals with and without ASCVD. The study found no evidence that the vaccine reduces cardiovascular events in patients with pre-existing ASCVD, but did reduce respiratory illness. Article 8: High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884413 Summary: standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. This analysis of the DANFLU-2 trial compared high-dose versus standard-dose influenza vaccines in adults with and without ASCVD. The study found no significant difference in cardiovascular or respiratory outcomes between the two vaccine types, regardless of ASCVD status. Full Episode Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Reticulated platelets in coronary artery disea

Welcome to Cardiology Today – Episode recorded on August 31, 2025. Your source for the latest cardiology research findings from top medical journals. Listen to This Episode Your browser does not support the audio element. Episode Summary This episode covers 8 recent cardiology research articles published in leading journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology. Featured Research Articles Article 1: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884768 Summary: This study found no significant differences in all-cause mortality, stroke, or rehospitalization between TAVR and SAVR at three years in low-risk patients aged 60-75 with severe aortic stenosis, supporting TAVR as a reasonable option in this population. However, there was a higher incidence of bioprosthetic valve failure after TAVR, warranting longer-term follow-up. Article 2: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884047 Summary: The PRADA II trial demonstrated that sacubitril-valsartan did not significantly reduce the incidence of cancer therapy-related cardiac dysfunction in patients undergoing adjuvant breast cancer treatment with anthracyclines and/or trastuzumab. These findings do not support the routine use of sacubitril-valsartan for primary prevention of cardiotoxicity in this setting. Article 3: Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879562 Summary: This study highlights the importance of intermediate-effect genetic variants (IEVs) in modulating the expression of hypertrophic cardiomyopathy (HCM). Understanding the clinical impact of these IEVs is crucial for unraveling the complex genetic architecture of HCM and improving risk stratification. Article 4: Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40878766 Summary: The DOUBLE-CHOICE trial showed that a minimalist anesthesia approach for transfemoral TAVI is non-inferior to standard of care regarding safety and efficacy. These results support the broader adoption of minimalist TAVI strategies to optimize resource utilization and patient outcomes. Article 5: Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40878676 Summary: This research identifies that in antiphospholipid syndrome (APS), the abnormal proliferation of microvascular endothelial cells leading to vasculopathy is driven by YAP1 and CCN2 signaling pathways. This discovery provides potential therapeutic targets for treating APS vasculopathy, where targeted treatment options are currently lacking. Article 6: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886179 Summary: The TAILORED-CHIP trial found that a tailored antiplatelet strategy involving early escalation and subsequent de-escalation based on platelet function testing did not significantly reduce major adverse cardiovascular events compared to a standard antiplatelet strategy in high-risk patients undergoing complex PCI. This suggests that routine tailoring of antiplatelet therapy based on platelet function in this setting may not provide additional benefit. Article 7: Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886161 Summary: This analysis of the GALACTIC-HF trial demonstrates that low serum magnesium concentrations are associated with increased risk of adverse cardiovascular outcomes in patients with heart failure with reduced ejection fraction (HFrEF). The findings suggest that magnesium status may be an important prognostic marker in HFrEF. Article 8: Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886132 Summary: This study indicates that first-degree relatives of individuals with elevated lipoprotein(a) levels have an increased risk of cardiovascular events. Screening first-degree relatives for elevated Lp(a) may identify individuals at risk who could benefit from early intervention.

Welcome to Cardiology Today – your source for the latest cardiology research findings. Articles Featured in This Episode: Article 1. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction., https://pubmed.ncbi.nlm.nih.gov/40879434 Article 2. Multidomain Rehabilitation for Older Patients with Myocardial Infarction., https://pubmed.ncbi.nlm.nih.gov/40879431 Article 3. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias., https://pubmed.ncbi.nlm.nih.gov/40879429 Article 4. Reduction of Antihypertensive Treatment in Nursing Home Residents., https://pubmed.ncbi.nlm.nih.gov/40879421 Article 5. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry., https://pubmed.ncbi.nlm.nih.gov/40886109 Your browser does not support the audio element. Cardiology Today provides concise summaries of the latest research from top cardiology journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.The post Cardiology Updates: Potassium, Rehab, and Novel Therapies 083125 first appeared on Cardiology Today.

Welcome to Cardiology Today – your source for the latest cardiology research findings. Articles Featured in This Episode: Article 1. Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction., https://pubmed.ncbi.nlm.nih.gov/40879434 Article 2. Multidomain Rehabilitation for Older Patients with Myocardial Infarction., https://pubmed.ncbi.nlm.nih.gov/40879431 Article 3. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias., https://pubmed.ncbi.nlm.nih.gov/40879429 Article 4. Reduction of Antihypertensive Treatment in Nursing Home Residents., https://pubmed.ncbi.nlm.nih.gov/40879421 Article 5. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry., https://pubmed.ncbi.nlm.nih.gov/40886109 Your browser does not support the audio element. Cardiology Today provides concise summaries of the latest research from top cardiology journals including NEJM, JACC, Circulation, European Heart Journal, and Nature Reviews Cardiology.The post Heart Failure, Potassium, and Mitral Valve Insights 083125 first appeared on Cardiology Today.